Biopharma Firm Applies to Produce Large Quantities of Controlled Meds
Published Date: 8/11/2025
Notice
Summary
Biopharmaceutical Research Company wants to get official approval to make large amounts of certain controlled substances. This affects anyone tracking or regulating these drugs and could speed up research and development. Keep an eye out for updates on approval timing and any related fees.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Application to Bulk-Manufacture Controlled Drugs
Biopharmaceutical Research Company has applied to be registered as a bulk manufacturer of basic classes of controlled substances. This affects people and organizations that track or regulate these drugs and could speed up research and development.
Watch for Approval Timing and Fees
The notice advises stakeholders to watch for updates on approval timing and any related fees. If you are an applicant, regulator, or otherwise involved with these drugs, future notices may announce when approval happens and whether fees apply.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-15161, Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals
Chattem Chemicals wants to get official approval to make large amounts of certain controlled substances. This affects anyone involved in drug manufacturing and regulation, as it could change who supplies these important chemicals. Keep an eye out for updates on approvals and any new rules that might come with this change.
Next: 2025-15164, Notice of Public Hearing and Request for Comments on the Fair Market Value and Maximum Economic Recovery for the Little Eccles Coal Lease by Application, UTU-92226, in Emery County, Utah
The Bureau of Land Management wants your thoughts on how much the coal in the Little Eccles lease in Emery County, Utah, is really worth and how much can be profitably mined. This affects local communities, coal companies, and anyone interested in land use and energy resources. Speak up soon—your comments could shape the lease’s future value and mining plans!